Funding Focus is a new series that analyzes the cash flow into the European Tech ecosystem. After we made a look at the biggest rounds this year, we are now turning off the largest offers in the Netherlands for H1.
Startups in the Netherlands only collected $ 503 million in the first quarter of this year (EUR 429 million)-the lowest quarterly total since the information in the COVID-19 pandemic. But three months later, the outlook improved.
The total financing for the first half of 2025 was $ 1.4 billion (€ 1.2 billion). That is after USD 1.8 billion (EUR 1.54 billion) at the same point last year, but compared to USD 1.1 billion (€ 940) in H1 2023.
The rebound was driven by a much stronger second quarter, in which startups secured USD 856 million (EUR 940 million) – a 70% plitue compared to the first quarter.
TNW Conference 2025 – this is a wrap!
Take a look at the highlights!
The leading of the dynamics is biotech, with half of the top -10 finance rounds in H1 from startups with a basis in the organic sciences. Here is the full list.
1.Azafaros – € 132 m
HQ: suffering
Azafaros develops small molecular medicines that aim at rare metabolic disorders. In June 2025, the company collected EUR 132 million in a series -B round.
2. Good – € 115 m €
HQ: Amsterdam
Finom runs a Pan-European Neobank for SMEs and entrepreneurs. It raised a 115 million € series C in June after a € 50 million Round of series B Last year.
3. MEWS – € 64 million
HQ: Amsterdam
Hospitality platform MEWS secured $ 75 million (64 million €) in March. In total, MEWS packed over $ 500 million (€ 425 million) So far it has been one of the best-financed scale-ups in the Netherlands.
4. The front – € 62m
HQ: Amsterdam
Toloka is a crowdsourcing platform that uses a global network of human workers to label and evaluate data – text, images, audio and more – for training and improving AI models. The business is part of the Dutch AI infrastructure company Negro.
In May Toloka collected $ 72 million (62 million €) in a financing round led by Jeff Bezos' investment company Bezos Expeditions.
5. Leyden Labs – € 60m
HQ: suffering
Leyden Labs develops intranasal medication to protect against respiratory viruses. In January it collected € 70 million (EUR 60 million) and raised its total amount $ 257 million (€ 220 million).
6. Alasta therapeutics – 56 m €
HQ: suffering
Alesta Therapeutics is another biotech startup of Leiden – home to one of the leading hub of Europe. The company focuses on the development of small molecular therapies for rare diseases that are taken orally. In January it increased $ 65n (56 million €) in Serie A -Financing.
7. Salvia bioelectronics – € 53 million
HQ: Eindhoven
The Salvia bioelectronics make soft brain implants for the treatment of chronic migraines with gentle electrical impulses. In May the startup increased 53 million € in series B financing.
8. Avidicure – 44 m €
HQ: Amsterdam
The avidi meadow develops antibody therapies to activate the immune system and treat cancer. In April it brought a strong seed round of EUR 44 million to accelerate research and development.
9. Piano – 38 m €
HQ: Amsterdam
Piano offers tools with which companies understand the online behavior of their customers and provide personalized content or offers to engage them and increase sales. In February it collected $ 45 million (EUR 38 million) in Series D Financing.
10. Vivici – 32.5 m €
Vivici is a food tech startup that uses precision fermentation to produce animal-free milk proteins. His proteins are designed in such a way that they replace traditional milk ingredients such as whey and casein. In February it increased 32.5 million € in Serie A -Financing.
Comments are closed.